<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85577">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01785550</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00042025</org_study_id>
    <nct_id>NCT01785550</nct_id>
  </id_info>
  <brief_title>Neuromuscular Ultrasound in ALS</brief_title>
  <official_title>Ultrasonography in Amyotrophic Lateral Sclerosis as a Predictor of Disease Progression and Tool in Diagnosis: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic Lateral Sclerosis (ALS) is a progressive fatal neurodegenerative disease
      affecting motor neurons. Early diagnosis is essential for the success of clinical trials and
      objective biomarkers are needed for monitoring disease progression.  Nerve and muscle
      ultrasound may provide this information.

      This study will collect pilot data to evaluate the value of muscle and nerve ultrasound to
      identify and monitor disease progression in ALS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Abnormalities at onset: Ultrasound vs. Electromyography</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ultrasound measures will be compared to electromyography measures at the patient's initial assessment.  The number of abnormal muscles will be counted using each technique and analyzed to determine if one test is superior.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ultrasound Predicting Outcome at 1 year</measure>
    <time_frame>1.5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The initial ultrasound measures and patient outcomes, as measured by standard validated scales, will be assessed at periodic intervals for one year.  Analysis will be performed to determine if ultrasound measures can predict the clinical course.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>ALS</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>No intervention to be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultrasound Group</arm_group_label>
    <description>All will receive nerve and muscle ultrasound.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ultrasound of nerve and muscle</intervention_name>
    <description>Ultrasound of 6 muscles and 2 nerves will be performed.</description>
    <arm_group_label>Ultrasound Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients referred to the electromyography laboratory for ALS.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects referred to the electromyography laboratory for ALS.

        Exclusion Criteria:

          -  Patients with known comorbid myopathy or neuropathy will be excluded from the study.

          -  Patients unable to provide their own consent will be excluded.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa D Hobson-Webb, M.D.</last_name>
      <phone>919-668-2277</phone>
      <email>lisa.hobsonwebb@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa D Hobson-Webb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 3, 2014</lastchanged_date>
  <firstreceived_date>February 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
